A complex essential oil and a product containing the same and use thereof

Abstract

The application belongs to the technical field of traditional Chinese medicine health care, and particularly relates to a compound essential oil, a product containing the compound essential oil and application thereof. The compound essential oil with anti-inflammatory and analgesic activity is composed of the following components in volume fraction: 0.1-2 parts of essential oil of folium artemisiae argyi, 0.1-2 parts of essential oil of ligusticum wallichii, 0.1-3 parts of essential oil of ginger, 0.1-2 parts of essential oil of rose, 3-8 parts of turpentine oil and 85-105 parts of grape seed oil. The compound essential oil is obtained by reasonably compounding different plant essential oils and combining scientific proportioning, and has good analgesic and anti-inflammatory effects. After the compound essential oil is prepared into a microemulsion preparation, the retention amount of effective components, eucalyptol, camphor and borneol, in the skin is significantly improved, the administration frequency can be effectively reduced, the production cost of the compound essential oil microemulsion preparation is saved, and a basis is provided for application and popularization of the compound essential oil.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine health care technology, specifically relating to a compound essential oil and products containing the compound essential oil and their applications. Background Technology

[0002] Anti-inflammatory and analgesic treatments are an important research direction in the medical field. Drugs for treating inflammation and pain include chemical drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, and COX-2 inhibitors, as well as traditional Chinese medicines with effective components as the main active ingredients, such as total alkaloids of Aconitum carmichaelii, total glucosides of Paeonia lactiflora, triptolide, corydaline, and sinomenine. Since most drugs for treating pain require long-term use, chemical drugs and some single components of traditional Chinese medicine can cause serious side effects such as nephrotoxicity and reproductive toxicity after long-term use. Therefore, further research and development of drug formulations with good anti-inflammatory and analgesic efficacy and low toxicity is needed.

[0003] my country boasts abundant traditional Chinese medicinal resources, and many herbs and natural products are widely studied for anti-inflammatory and analgesic treatments. Essential oils, in particular, are extracted from the leaves, flowers, seeds, fruits, and roots of plants using methods such as steam distillation, cold pressing, enfleurage, and supercritical carbon dioxide extraction. Due to their natural origin, they are widely considered closer to nature than synthetic drugs, representing a healthier and more sustainable option. Current research confirms the anti-inflammatory and analgesic effects of plant essential oils; however, the pharmacological basis of single essential oils is limited, making it difficult to completely cure or control the development of organic lesions affecting multiple organs. Therefore, the research and development of compound essential oils with good anti-inflammatory and analgesic effects by mixing multiple essential oils in specific proportions is urgently needed. Summary of the Invention

[0004] The purpose of this invention is to address the shortcomings of existing technologies by providing a compound essential oil, products containing the compound essential oil, and their applications. Through the rational combination and scientific proportioning of different plant essential oils, the resulting compound essential oil exhibits excellent analgesic and anti-inflammatory effects. Formulating the compound essential oil into a microemulsion significantly increases the retention of its active ingredients, eucalyptol, camphor, and borneol, in the skin, effectively reducing the frequency of administration and saving on the production costs of the compound essential oil microemulsion.

[0005] To solve the above-mentioned technical problems of the present invention, the present invention provides the following technical solution:

[0006] The first objective of this invention is to provide a compound essential oil with anti-inflammatory and analgesic activity, which is composed of the following components in parts by volume: 0.1-2 parts of Artemisia argyi essential oil, 0.1-2 parts of Ligusticum chuanxiong essential oil, 0.1-3 parts of ginger essential oil, 0.1-2 parts of rose essential oil, 3-8 parts of turpentine oil, and 85-105 parts of grapeseed oil.

[0007] Artemisia argyi essential oil is extracted from the dried leaves of Artemisia argyi, a plant in the Asteraceae family. Its main chemical components are monoterpenes and their derivatives, as well as sesquiterpenes and their derivatives, such as 1,8-cineole, β-pinene, thujone, L-camphor, fennelene, terpinene-4-ol, α-terpineol, camphor, borneol, α-thujone, β-caryophyllene, caryophyllene, and geraniol D. Studies have found that applying or using Artemisia argyi essential oil topically or as a poultice can improve pain relief in the treatment of shoulder and lower back pain.

[0008] Ligusticum chuanxiong essential oil has the effects of clearing the meridians and promoting blood circulation. It can be used to treat injuries from falls and blows, rheumatic pain, headaches and other diseases. In addition, it also has the effects of regulating qi, relieving pain and dispelling wind.

[0009] Ginger essential oil is extracted from the dried rhizome of ginger, a plant in the ginger family. The main components of ginger essential oil are 1R-α-pinene, camphene, β-pinene, β-phellandrene, β-geraniol, eucalyptol, linalool, borneol, citral, α-terpineol, geraniol acetate, α-curcumene, zingiberene, α-farnesene, β-myrrhene, and β-elemene. Ginger essential oil helps to disperse blood stasis and heal wounds; it is also effective for oily and pale skin. It has aphrodisiac properties, relieves flatulence, and is particularly helpful in improving internal dampness, such as in cases of influenza, excessive phlegm, and runny nose. It also has expectorant, antipyretic, mild laxative, and warming effects on the body.

[0010] Rose essential oil is the most expensive essential oil in the world, known as the "Queen of Essential Oils." Its fragrant aroma, transmitted through the olfactory nerve, enters the brain and stimulates the frontal lobe to secrete endorphins and enkephalins, creating a state of mental comfort—the best remedy for protecting the mind. It also has anti-inflammatory and antibacterial properties, can prevent infectious diseases, reduce inflammation and spasms, promote cell metabolism and regeneration, making life better. Furthermore, it can regulate endocrine organs, promote hormone secretion, act as an aphrodisiac, and nourish the body, promoting healthy physiological and psychological development. Suitable for all skin types, it provides firming and soothing properties, nourishes the skin, and slows down aging.

[0011] Turpentine is a liquid extracted from the resin of coniferous plants by distillation or other methods. Its main component is terpenes, which can relieve muscle pain, joint pain, neuralgia, and sprains.

[0012] Grape seed oil contains two very important elements: linoleic acid and proanthocyanidins. Linoleic acid can fight free radicals, combat aging, aid in the absorption of vitamins C and E, strengthen the elasticity of the circulatory system, reduce UV damage, protect collagen in the skin, improve varicose veins and edema, and prevent melanin deposition. Proanthocyanidins protect blood vessel elasticity, shield the skin from UV damage, prevent the damage to collagen and elastin fibers, maintain the skin's elasticity and firmness, and prevent sagging and wrinkles. It has strong penetrating power, is refreshing and non-greasy, and is easily absorbed by the skin, making it suitable for all skin types.

[0013] Preferably, the compound essential oil also includes one or more of the following components in parts by volume:

[0014] Angelica essential oil 0.1-2 parts, lavender essential oil 0.1-3 parts, saffron essential oil 0.1-2 parts, rosemary essential oil 0.1-2 parts.

[0015] Angelica essential oil is extracted from the root of Angelica sinensis and contains artemisinin, which has the effects of regulating menstruation and relieving pain, improving anemia, protecting the cardiovascular system, preventing and treating asthma, moisturizing the intestines and relieving constipation, and improving the body's immunity.

[0016] Lavender essential oil is extracted from the flowers of the lavender plant, a member of the Lamiaceae family. Lavender essential oil is one of the preferred natural fragrances and medicinal herbs among essential oils. Its active ingredients mainly consist of compounds such as linalool, camphor, linalyl acetate, linalool, α-terpineol, eucalyptol, trans-caryophyllene, geraniol, and bisabolol. It can clear heat and detoxify, cleanse the skin, control oil production, whiten and brighten skin, reduce wrinkles and rejuvenate the skin, remove eye bags and dark circles, and promote the regeneration and recovery of damaged tissues. Lavender essential oil also has a calming effect on the heart, can lower high blood pressure, soothe palpitations, and is helpful for insomnia.

[0017] Saffron essential oil contains substances such as crocin, which can slow down skin oxidation and prevent aging. Long-term use of saffron oil for massage can revitalize the skin, relieve roughness, improve dullness, lighten pigmentation, and brighten skin tone.

[0018] Rosemary essential oil's main component is 2-oxalool, which has a strong astringent effect, conditioning oily and unclean skin, promoting blood circulation, and stimulating hair regeneration. Medicinally, it can treat neurological disorders and be used to make ointments for headaches and rheumatism. It is also an ideal natural preservative with anti-inflammatory and powerful antibacterial properties.

[0019] This invention obtains a compound essential oil with good analgesic and anti-inflammatory effects by rationally combining different plant essential oils and combining them in a scientific ratio.

[0020] In one embodiment of the present invention, the volume fractions of each component in the compound essential oil are as follows:

[0021] 0.5 parts Artemisia argyi essential oil, 0.5 parts Angelica sinensis essential oil, 0.5 parts Ligusticum chuanxiong essential oil, 0.5 parts Ginger essential oil, 0.5 parts Lavender essential oil, 0.5 parts Rose essential oil, 5 parts Turpentine oil, and 92 parts Grapeseed oil.

[0022] In another embodiment of the present invention, the volume fractions of each component in the compound essential oil are as follows:

[0023] 0.5 parts Artemisia argyi essential oil, 0.5 parts Saffron essential oil, 0.5 parts Ligusticum chuanxiong essential oil, 0.5 parts Ginger essential oil, 0.5 parts Rosemary essential oil, 0.5 parts Rose essential oil, 5 parts Turpentine oil, and 92 parts Grapeseed oil.

[0024] A second objective of this invention is to provide the application of the above-mentioned compound essential oil in the preparation of products with anti-inflammatory and analgesic properties.

[0025] A third objective of this invention is to provide a method for preparing the above-mentioned compound essential oil, wherein the components of the compound essential oil are mixed evenly according to volume parts.

[0026] A fourth objective of this invention is to provide a compound essential oil product comprising the aforementioned compound essential oil and excipients acceptable for use in health foods and / or pharmaceuticals.

[0027] The fifth objective of this invention is to provide a compound essential oil microemulsion comprising, by weight percentage: 3%-5% compound essential oil, 8%-12% emulsifier, 4%-6% anhydrous ethanol, and the balance being purified water.

[0028] Preferably, the emulsifier is at least one of Tween 80, RH40, propylene glycol alginate, carrageenan, lactic acid fatty acid glycerides, and pine resin glycerides.

[0029] Using pure compound essential oils alone results in high production costs and difficulty in preservation. The inventors discovered that by preparing compound essential oils into microemulsions, the retention of active ingredients such as eucalyptol, camphor, and borneol in the skin can be significantly increased. This can effectively reduce the frequency of administration, save on the production costs of compound essential oil microemulsions, and facilitate storage, thus providing a foundation for the application and promotion of compound essential oils.

[0030] In one embodiment of the present invention, the compound essential oil microemulsion comprises, by mass percentage, 4% of compound essential oil group 1, 7.1% of Tween-80, 3.6% of RH40, 5.3% of anhydrous ethanol, and the balance being purified water.

[0031] The beneficial effects of this invention are:

[0032] 1. By rationally combining different plant essential oils and using scientific proportions, a compound essential oil with good analgesic and anti-inflammatory effects is obtained. The preparation method of this compound essential oil is simple and convenient to operate.

[0033] 2. Formulating compound essential oils into microemulsions significantly increases the retention of active ingredients such as eucalyptol, camphor, and borneol in the skin, effectively reducing the frequency of administration, saving production costs of compound essential oil microemulsions, and facilitating storage, thus providing a foundation for the application and promotion of compound essential oils. Attached Figure Description

[0034] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0035] Figure 1 This is a particle size distribution diagram of the compound essential oil microemulsion;

[0036] Figure 2 Zeta potential diagram of compound essential oil microemulsion;

[0037] Figure 3 The Qn-t graph of eucalyptol;

[0038] Figure 4 The Qn-t graph of camphor;

[0039] Figure 5 This is the Qn-t graph of borneol. Detailed Implementation

[0040] This invention provides a compound essential oil with anti-inflammatory and analgesic activity, which is composed of the following components in parts by volume: 0.1-2 parts of Artemisia argyi essential oil, 0.1-2 parts of Ligusticum chuanxiong essential oil, 0.1-3 parts of ginger essential oil, 0.1-2 parts of rose essential oil, 3-8 parts of turpentine oil, and 85-105 parts of grapeseed oil.

[0041] In this invention, the compound essential oil also includes one or more of the following components in parts by volume:

[0042] Angelica essential oil 0.1-2 parts, lavender essential oil 0.1-3 parts, saffron essential oil 0.1-2 parts, rosemary essential oil 0.1-2 parts.

[0043] Unless otherwise specified, all raw materials used in this invention are commercially available products in the field.

[0044] This invention provides an application of a compound essential oil in the preparation of products with anti-inflammatory and analgesic effects. This compound essential oil exhibits good anti-inflammatory and analgesic effects, and its main components are eucalyptol, camphor, and borneol.

[0045] This invention provides a method for preparing compound essential oils, which involves uniformly mixing the components of the compound essential oil according to their volume proportions. This preparation method is simple, convenient to operate, and has low production costs.

[0046] This invention provides a compound essential oil product, characterized in that it includes the above-mentioned compound essential oil and excipients acceptable for health foods and / or pharmaceuticals.

[0047] This invention provides a compound essential oil microemulsion, comprising the following components by mass percentage: 3%-5% compound essential oil, 8%-12% emulsifier, 4%-6% anhydrous ethanol, and the balance purified water.

[0048] In this invention, the emulsifier is at least one of Tween 80, RH40, propylene glycol alginate, carrageenan, lactic acid fatty acid glycerides, and pine resin glycerides.

[0049] To further illustrate the present invention, the following detailed description, in conjunction with examples, provides a compound essential oil and products containing the compound essential oil, as well as their applications, but these should not be construed as limiting the scope of protection of the present invention.

[0050] Unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, the formulations involved in the following examples are all commercially available products that can be purchased from the market.

[0051] The present invention will be further illustrated below with reference to the embodiments:

[0052] The compound essential oil of this embodiment includes components in the volume parts shown in the table below.

[0053] Table 1. Compound essential oil formulations from Examples 1-6

[0054]

[0055] After the compound essential oils of Examples 1-6 were mixed evenly according to the volume parts in Table 1, compound essential oil groups 1-6 were obtained respectively.

[0056] Experimental Example 1:

[0057] To further demonstrate the advantages of the present invention, the analgesic and anti-inflammatory effects of the above-mentioned compound essential oil groups 1-6 were verified.

[0058] (I) Analgesia Experiment

[0059] Animal screening: Female mice weighing 18-22g were placed one by one into a hot plate apparatus to measure their pain threshold (the time from being placed into the hot plate to licking their hind paws). Mice with a pain threshold of less than 5 seconds or greater than 30 seconds, as well as mice that jumped upwards, were removed. Qualified mice were selected for formal experiments.

[0060] Grouping and administration: Qualified mice were randomly divided into a control group, compound essential oil groups 1-6, and a positive control group (indomethacin 20 mg / kg), with 9 mice in each group. The test drug was administered by gavage (20 mL / kg), while the control group received an equal volume of physiological saline. Administration continued for 4 days; the positive control group was administered by gavage, with a single dose on the last day. Half an hour after administration, mice were placed on a hot plate in the order of administration to record their pain threshold and calculate the analgesic rate.

[0061] Analgesia rate = (Pain threshold of treatment group - Pain threshold of control group) / Pain threshold of control group * 100%.

[0062] The analgesic effects of different formulations of compound essential oils on mice are shown in Table 2.

[0063] Table 2. Analgesic effects of different compound essential oil formulations in mice.

[0064]

[0065] Note: *p<0.05 compared with the control group.

[0066] As shown in Table 2, compared with the control group, the pain threshold of mice in groups 1 and 2 was significantly prolonged (p<0.05). This indicates that the compound essential oils in the two formulations of Examples 1 and 2 can prolong the response time of mice to pain induced by hot plates, indicating that they have a significant analgesic effect. The analgesic rates were 20.83% and 16.66%, respectively.

[0067] (II) Anti-inflammatory experiment

[0068] Female mice weighing 18-22g were randomly divided into a control group, compound essential oil groups 1-6, and a positive control group (indomethacin 20mg / kg), with 11 mice in each group. The test drug was administered by gavage (20mL / kg), while the control group received an equal volume of physiological saline. The administration was repeated for 4 consecutive days. The positive control group was administered once on the last day. 0.5h after the last administration, 50μL of xylene was applied to both the anterior and posterior surfaces of the right ear of the mice to create a mouse ear swelling and inflammation model.

[0069] One hour after modeling, the mice were euthanized by cervical dislocation, and both ears were cut off along the auricle baseline. Circular ear pieces were punched out at the same location using a 6mm punch, and the pieces were precisely weighed using an analytical balance to calculate the swelling degree (the difference in mass between the two ears) and the inhibition rate.

[0070] Inhibition rate = (swelling degree of control group - swelling degree of treatment group) / swelling degree of control group * 100%.

[0071] The results of the anti-inflammatory effects of different compound essential oil formulations on mice are shown in Table 3.

[0072] Table 3. Anti-inflammatory effects of different compound essential oil formulations in mice.

[0073]

[0074] Note: Compared with the control group, *p<0.05, **p<0.01

[0075] As shown in Table 3, compared with the control group, the ear swelling of mice in groups 1, 2, 3, 4, and 6 was significantly reduced (p<0.05 or p<0.01), with swelling inhibition rates of 62.65%, 67.32%, 68.00%, 54.18%, and 54.96%, respectively. This indicates that the compound essential oils in groups 1, 2, 3, 4, and 6 can reduce the acute inflammatory response induced by xylene, demonstrating their significant anti-inflammatory effect. Among them, the anti-inflammatory effects of compound essential oils in groups 1, 2, and 3 were more significant.

[0076] In summary, compound essential oil groups 1 and 2 significantly prolonged the pain threshold in mice, demonstrating a marked analgesic effect. Compound essential oil groups 1, 2, 3, 4, and 6 significantly reduced ear swelling in mice, exhibiting a significant anti-inflammatory effect. Based on the combined results of these two experiments, groups 1 and 2 showed the most significant anti-inflammatory and analgesic effects, indicating that these two formulas can be considered as alternative formulas for analgesia and anti-inflammation.

[0077] Experimental Example 2:

[0078] Preparation of compound essential oil microemulsion: Based on the experimental results of Experiment Example 1 above, Compound Essential Oil Group 1 (0.5 mL of Artemisia argyi essential oil, 0.5 mL of Ligusticum chuanxiong essential oil, 0.5 mL of ginger essential oil, 0.5 mL of rose essential oil, 5 mL of turpentine oil, 92 mL of grapeseed oil, 0.5 mL of Angelica sinensis essential oil, and 0.5 mL of lavender essential oil) was selected to prepare a compound essential oil microemulsion. The specific formula composition is: 4% Compound Essential Oil Group 1, 7.1% Tween-80, 3.6% RH40, 5.3% anhydrous ethanol, and the balance being purified water.

[0079] 2.1 Particle size, PDI, and Zeta potential detection

[0080] The particle size, polydispersity index, and zeta potential of the compound essential oil microemulsion were determined using a Malvern nanoparticle size analyzer. The microemulsion sample was poured into a cuvette up to the instrument's graduation mark, and the measurement was repeated three times. The test results are shown in Table 4.

[0081] Table 4. Particle size, PDI, and zeta potential of compound essential oil microemulsions

[0082]

[0083] As shown in Table 4, the average particle size of the compound essential oil microemulsion was 23.98 nm, the PDI was 0.246, and the potential was -1.77 mV. The particle size distribution diagram of the compound essential oil microemulsion is shown below. Figure 1 See Zeta potential diagram Figure 2 .

[0084] 2.2 Viscosity and pH Testing

[0085] A suitable amount of the compound essential oil microemulsion was taken and its acidity and viscosity were measured at room temperature using a pH meter and a rotational viscometer, respectively. The measurements were repeated three times. The results of the acidity and viscosity of the compound essential oil microemulsion are shown in Table 5.

[0086] Table 5. pH value and viscosity of compound essential oil microemulsions

[0087]

[0088] As can be seen from Table 5, the average pH value of the compound essential oil microemulsion is 6.14, which meets the requirement of weak acidity of the skin and can be used on human skin. The average viscosity is 3.28, which meets the low viscosity property of microemulsion.

[0089] 2.3 Conductivity Detection

[0090] A suitable amount of the compound essential oil microemulsion was taken and its conductivity was measured at room temperature using a conductivity meter. The measurement was repeated three times, and the conductivity of the compound essential oil microemulsion was 439, 424, and 437 μS / cm, respectively, with an average conductivity of 433.33 μS / cm, indicating that the physicochemical properties of the compound essential oil microemulsion are relatively stable.

[0091] Experimental Example 3: Transdermal Release Test

[0092] A transdermal release test was conducted on the compound essential oil microemulsion in Experiment Example 2. The specific procedures are as follows:

[0093] 3.1 Preparation of mouse ex vivo skin

[0094] Remove the hair from the mouse's abdomen with hair removal cream. After the mouse is euthanized, immediately cut off the abdominal skin, clean off the attached fat and subcutaneous tissue, carefully wash with saline solution and dry off excess moisture, then wrap in aluminum foil and freeze at -20°C for later use.

[0095] 3.2 Franz diffusion cell test

[0096] Preparation of blank receiving solution: Mix anhydrous ethanol and physiological saline in a 3:7 ratio and sonicate for 10 minutes. Place the rotor in the receiving chamber and add 15 mL of the receiving solution. Immerse the cryopreserved mouse 3D skin in physiological saline for 30 minutes, remove it, blot dry with filter paper, and cut it into appropriate sizes (enough to cover the receiving chamber by 1.13 cm). 2 The mouse skin was laid flat with the epidermis facing the release tank and the dermis facing the receiving tank, clamped and fixed, and all air bubbles in the receiving liquid were removed. 1 mL of the compound essential oil microemulsion sample was precisely pipetted and placed on the mouse skin. The release tank was then sealed with a sealing film. Six parallel groups were tested. The control group consisted of an ethanol solution of the compound essential oil. The specific formulation of the ethanol solution was 4% compound essential oil (Group 1) and the remainder anhydrous ethanol.

[0097] The intelligent transdermal testing instrument was filled with water, and the circulating water bath temperature was 37.5℃ with a stirring speed of 300 r / min for 30 min of pre-equilibration. At 1, 2, 4, 6, 8, 10, 12, and 24 hours after the start of timing, 1 mL of the receiving liquid was precisely pipetted, and 1 mL of blank receiving liquid was added. The collected receiving liquid was centrifuged at 4℃ for 20 min, and then extracted with 1 mL of ethyl acetate. After standing, the supernatant was filtered through a 0.22 μm organic filter membrane and placed in a vial. The cumulative permeation amount Qn (μg / cm³) of the index components eucalyptol, camphor, and borneol in the compound essential oil microemulsion was calculated using gas chromatography. 2 The gas chromatography conditions are as follows:

[0098] An HP-5 (30m × 320μm × 0.25m) capillary column was used with nitrogen as the carrier gas. The temperature was programmed, starting at 90℃ and holding for 2 min; then increased at 5℃·min. -1 Rise to 110℃; then increase by 10℃·min -1 The temperature was raised to 150°C and held for 10 minutes. The detector temperature was 250°C, the injection port temperature was 200°C, the injection volume was 1 μL, and the split ratio was 5:1.

[0099] Plotting the cumulative transmittance Qn on the ordinate and time t on the abscissa yields the Qn-t graph. The data are then fitted using zero-order, first-order, and Higuchi equations, respectively.

[0100] The calculation formula is:

[0101]

[0102] Where: Qn is the cumulative transmittance per unit area at the nth time point (μg / cm²). 2 Cn and Ci are the drug concentrations (μg / mL) measured at the nth and ith time points, respectively; V is the volume of receiving solution added (15 mL); Vi is the volume of each sample taken (1 mL); and A is the effective transdermal area (1.13 cm²). 2 The specific results of the penetration rate tests for each component are as follows.

[0103] 3.2.1 Penetration rate of eucalyptus oil

[0104] The cumulative permeation of eucalyptol, the index component of the compound essential oil microemulsion, through transdermal penetration is shown in Table 6. Based on this data, a Qn-t plot of eucalyptol is obtained. Figure 3 .

[0105] Table 6 Cumulative Permeation of Eucalyptus Oil

[0106]

[0107] As shown in Table 6, the cumulative permeation of eucalyptol in the compound essential oil microemulsion and the compound essential oil ethanol solution at 24 h was 148.24 ± 10.83 μg / cm³, respectively. 2 and 103.33±3.98μg / cm 2 The cumulative permeation in the microemulsion system at each time point was greater than that in the ethanol solution, indicating that the microemulsion formulation can effectively increase the transdermal permeation of eucalyptol. The transdermal permeation of eucalyptol in the compound essential oil microemulsion best fits the Higuchi fitting equation; the specific fitting equation data are shown in Table 7.

[0108] Table 7. Qn-t fitting equation for eucalyptol

[0109]

[0110] The Qn-t fitting equation of eucalyptol in Table 7 shows that eucalyptol has a sustained-release effect in compound essential oil microemulsions.

[0111] 3.2.2 Camphor Permeability

[0112] The cumulative permeation of camphor, the index component of the compound essential oil microemulsion, through dermal penetration is shown in Table 8. A Qn-t plot of camphor was obtained based on this data. Figure 4 .

[0113] Table 8 Cumulative Permeability of Camphor

[0114]

[0115] As shown in Table 8, the cumulative permeation of camphor in the compound essential oil microemulsion and the compound essential oil ethanol solution at 24 hours was 370.41 ± 13.99 μg / cm³. 2 and 272.79±11.43μg / cm 2 The cumulative permeation in the microemulsion system at each time point was greater than that in the ethanol solution, indicating that the compound essential oil microemulsion formulation can effectively increase the transdermal permeation of camphor. Specific fitting equation data are shown in Table 9.

[0116] Table 9. Qn-t fitting equation for camphor

[0117]

[0118] Table 9 shows that camphor permeation through the skin in compound essential oil microemulsions best matches the Higuchi fitting equation, indicating that camphor has a sustained-release effect in compound essential oil microemulsion formulations.

[0119] 3.2.3 Penetration rate of borneol

[0120] The cumulative permeation of borneol, the index component of the compound essential oil microemulsion, through transdermal penetration is shown in Table 10. Based on this data, a Qn-t plot of borneol was obtained. Figure 5 .

[0121] Table 10 Cumulative Permeability of Borneol

[0122]

[0123] As shown in Table 10, the cumulative permeation of borneol in the compound essential oil microemulsion and the compound essential oil ethanol solution at 24 hours was 257.04 ± 12.56 μg / cm³. 2 and 188.82±11.32μg / cm 2 The cumulative permeation in the microemulsion system at each time point was greater than that in the ethanol solution, indicating that the compound essential oil microemulsion formulation can effectively increase the transdermal permeation of borneol. Specific fitting equation data are shown in Table 11.

[0124] Table 11 Qn-t fitting equations for borneol

[0125]

[0126] Table 11 shows that borneol's transdermal penetration in compound essential oil microemulsions best matches the Higuchi fitting equation, indicating that borneol has a sustained-release effect in compound essential oil microemulsion formulations.

[0127] 3.2.4 Investigation of Permeation Kinetics

[0128] Linear regression was performed on the linear portion of the Qn-t curves for the three index components, and the slope of the resulting line is the steady-state transdermal rate (Js). The results are shown in Table 12.

[0129] Table 12 Osmotic kinetic parameters of eucalyptus oil, camphor, and borneol (n=6)

[0130]

[0131] As shown in Table 12, the transdermal penetration rates of eucalyptol in compound essential oil microemulsions and compound essential oil ethanol solutions were 4.6566 and 3.2561 μg·cm⁻¹, respectively. -2 ·h -1 The transdermal penetration rates of camphor in compound essential oil microemulsions and compound essential oil ethanol solutions were 10.491 and 7.6263 μg·cm⁻¹, respectively. -2 ·h -1 The transdermal penetration rates of borneol in compound essential oil microemulsions and compound essential oil ethanol solutions were 5.3018 and 3.8397 μg·cm⁻¹, respectively. -2 ·h -1 The transdermal penetration rates of the three indicator components in the microemulsion were all greater than those in the ethanol solution, indicating that microemulsion formulations can effectively improve the penetration rate of active ingredients.

[0132] Experimental Example 3: Skin Retention Test

[0133] After sampling at 24 hours following the transdermal test, a circular piece of skin was cut to the size of the receiving pool opening. Excess drug on the skin surface was washed off with physiological saline and dried with filter paper. 1 mL of methanol was accurately pipetted into a 2 mL centrifuge tube, and the minced skin was placed inside. The tube was centrifuged at 3000 rpm for 20 min at 4°C. The supernatant was filtered through a 0.22 μm filter membrane, and the drug retention in the skin was determined using gas chromatography under the following conditions:

[0134] An HP-5 (30m × 320μm × 0.25m) capillary column was used with nitrogen as the carrier gas. The temperature was programmed, starting at 90℃ and holding for 2 min; then increased at 5℃·min. -1 Rise to 110℃; then increase by 10℃·min -1 The temperature was raised to 150°C and held for 10 minutes. The detector temperature was 250°C, the injection port temperature was 200°C, the injection volume was 1 μL, and the split ratio was 5:1.

[0135] The results are shown in Table 13.

[0136] Table 13 Skin Retention Amounts of Eucalyptus Oil, Camphor, and Borneol (n=6)

[0137]

[0138] Table 13 shows that the retention amounts of eucalyptol, camphor, and borneol in the compound essential oil microemulsion group were 25.98±2.34 μg, 17.01±1.89 μg, and 14.35±1.04 μg, respectively, while those in the compound essential oil ethanol solution group were 20.73±1.73 μg, 11.29±0.63 μg, and 10.94±0.93 μg, respectively. Compared with the ethanol solution, the microemulsion system can significantly increase the retention amount of active ingredients in the skin, thereby reducing the frequency of administration.

[0139] Finally, it should be noted that the above examples are merely some specific embodiments of the present invention. Obviously, the present invention is not limited to the above embodiments and many variations are possible. All variations that can be directly derived or conceived by those skilled in the art from the disclosure of the present invention should be considered within the scope of protection of the present invention.

Claims

1. A compound essential oil with anti-inflammatory and analgesic activity, characterized in that: It consists of the following components in parts by volume: 0.5 parts Artemisia argyi essential oil, 0.5 parts Angelica sinensis essential oil, 0.5 parts Ligusticum chuanxiong essential oil, 0.5 parts Ginger essential oil, 0.5 parts Lavender essential oil, 0.5 parts Rose essential oil, 5 parts Turpentine oil, and 92 parts Grapeseed oil.

2. The use of the compound essential oil of claim 1 in the preparation of a drug with anti-inflammatory and analgesic properties.

3. The method for preparing the compound essential oil according to claim 1, characterized in that, Mix the components of the compound essential oil evenly according to their volume proportions.

4. A compound essential oil microemulsion, characterized in that: By mass percentage, it includes the following components: The compound essential oil of claim 1 comprises 3%-5%, emulsifier 8%-12%, anhydrous ethanol 4%-6%, and the balance being purified water.

5. The compound essential oil microemulsion according to claim 4, characterized in that: The emulsifier is at least one of Tween 80, RH40, propylene glycol alginate, carrageenan, lactic acid fatty acid glycerides, and pine resin glycerides.

Images